RDHL Redhill Biopharma Ltd.

-0.2  -2%
Previous Close 8.1
Open 8.03
Price To Book 4.39
Market Cap 224112651
Shares 28,368,690
Volume 16,346
Short Ratio
Av. Daily Volume 56,869

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2019.
Nontuberculous mycobacteria (NTM) infections
Phase 2a enrolment to be completed 2H 2019.
Phase 1/2 poster presentation at EORTC-NCI-AACR November 16, 2018.
Refractory or relapsed multiple myeloma - cancer
NDA resubmission announced November 1, 2017. Noted December 5, 2017 that an Incomplete Response Letter has been received from the FDA and termination of license agreement with IntelGenx Corp.
Phase 3 data released July 30, 2018. Primary endpoint met but further trial required.
Crohn’s disease
Phase 3 trial met primary endpoint. NDA filing 1H 2019.
H. pylori
Phase 3 top-line data released June 14, 2017 - primary endpoint met. Additional Phase 3 trial planned.
Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05. Follow up analysis identfied p value = 0.036. Phase 3 trial planned.
Phase 2 initiated October 2016.
Hepatocellular carcinoma (HCC) - cancer

Latest News

  1. RedHill Biopharma to Present at Three Conferences in April
  2. RedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference
  3. RedHill Biopharma to Present at the 31st Annual ROTH Conference
  4. RedHill Biopharma Announces New European and Japanese Patents for Talicia®
  5. RedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights
  6. RedHill Biopharma to Host Full-Year 2018 Financial Results Conference Call on February 26, 2019
  7. RedHill Biopharma Strengthens Management Team with Appointment of Rick D. Scruggs as Chief Operating Officer, U.S. Operations
  8. RedHill Biopharma to Present at the 8th Annual SVB Leerink Healthcare Conference
  9. RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection
  10. RedHill closes $20M public offering to prep commercialization of new drug
  11. RedHill Biopharma Announces Closing of $20 Million Underwritten Offering
  12. RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering
  13. RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
  14. RedHill Biopharma's antibiotic succeeds in late-stage study
  15. RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection
  16. RedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference
  17. IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
  18. RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium
  19. RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights
  20. RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018